Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Be47d6082c124dafeda298bcd23e4f3fc> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Be47d6082c124dafeda298bcd23e4f3fc NCIT_P378 "NCI" @default.
- Be47d6082c124dafeda298bcd23e4f3fc type Axiom @default.
- Be47d6082c124dafeda298bcd23e4f3fc annotatedProperty IAO_0000115 @default.
- Be47d6082c124dafeda298bcd23e4f3fc annotatedSource NCIT_C172205 @default.
- Be47d6082c124dafeda298bcd23e4f3fc annotatedTarget "A cancer vaccine consisting of a combination of two vaccines, a prime pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and a boost HPV16 L2/E6/E7 fusion protein TA-CIN vaccine, with potential immunostimulating and antineoplastic activities. pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine is an antigen-specific DNA cancer vaccine consisting of the coding sequences of a signal peptide (pNGVL4a-Sig), a detox form of the human papillomavirus type 16 (HPV-16) antigen E7, and the heat shock protein 70 (HSP70). Upon administration, this prime vaccine may generate potent cytotoxic CD8(+) T-cell responses against E7-expressing tumor cells, resulting in tumor cell death. HPV16 L2/E6/E7 fusion protein TA-CIN vaccine is a recombinant human papillomavirus (HPV), genetically engineered fusion protein vaccine in which the three HPV16 viral proteins L2, E6 and E7 are fused together in a single tandem fusion protein (TA-CIN; HPV16 L2\E6\E7). Upon administration, this boost vaccine may stimulate the immune system to generate HPV16 E6\E7-specific CD4+ and CD8+ T-cell responses as well as the induction of L2-specific antibodies. In addition, this vaccine may prevent infection and the development of other HPV16-associated diseases. L2, a minor viral capsid protein, is able to induce a strong antibody response against certain HPV types." @default.